Amgen Inc. (NASDAQ:AMGN) Holdings Raised by X Square Capital LLC

X Square Capital LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,955 shares of the medical research company’s stock after buying an additional 341 shares during the period. Amgen comprises approximately 2.0% of X Square Capital LLC’s holdings, making the stock its 10th biggest holding. X Square Capital LLC’s holdings in Amgen were worth $4,497,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Strategic Financial Concepts LLC bought a new stake in shares of Amgen in the 2nd quarter worth about $26,000. Hershey Financial Advisers LLC bought a new stake in shares of Amgen in the 2nd quarter worth about $30,000. nVerses Capital LLC bought a new stake in shares of Amgen in the 2nd quarter worth about $31,000. Bbjs Financial Advisors LLC bought a new stake in shares of Amgen in the 2nd quarter worth about $33,000. Finally, Matrix Trust Co acquired a new position in shares of Amgen in the 3rd quarter valued at about $36,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 1.5 %

AMGN stock opened at $314.90 on Thursday. Amgen Inc. has a 52 week low of $249.70 and a 52 week high of $346.85. The company has a market capitalization of $168.92 billion, a price-to-earnings ratio of 44.99, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The firm’s 50-day moving average is $325.77 and its two-hundred day moving average is $313.12. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter last year, the firm posted $5.00 earnings per share. The firm’s quarterly revenue was up 20.1% compared to the same quarter last year. On average, analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.86%. Amgen’s payout ratio is currently 128.57%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on AMGN shares. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Sanford C. Bernstein started coverage on shares of Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. TD Cowen lifted their price target on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Finally, Argus lifted their price target on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $332.55.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.